A New Antipsychotic Drug, Quetiapine (Seroquel),in Clinical Practice

Authors: F. Faltus;  J. Horáček;  D. Seifertová
Authors‘ workplace: Psychiatrická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. J. Raboch, DrSc. Psychiatrické centrum Praha, ředitel prof. MUDr. C. Höschl, DrSc.
Published in: Čes. a slov. Psychiat., , 2000, No. 2, pp. 77-85.


Quetiapine (Seroquel) is a new atypical dibenzothiazepine antipsychotic indicated for the treat-ment of schizophrenia. Like clozapine, quetiapine binds with a variety of neurotrainsmitter re-ceptor sites. Quetiapine has the greatest affinity for a1-adrenergic, H1-histaminergic and s(sigma) receptors. It has also an appreciable affinity for 5HT2-serotonergic a2 adrenergic andD2-dopaminergic receptors. The advance is virtually no affinity for benzodiazepine and muscari-nergic receptors. The beneficial receptor profile of quetiapine is responsible for the unique clini-cal characteristics. The efficacy in relation to schizophrenic symptoms is comparable withhaloperidol and chlorpromazine. Quetiapine produces only a minimum of side effects. The inci-dence of extrapyramidal symptoms is not different form placebo and quetiapine is not associatedwith increases in plasma prolactin levels. Quetiapine treatment is not associated with ECG abnor-malities, haematotoxicity and there are only few significant drug interactions.

Key words:
quetiapine, Seroquel, schizophrenia, atypical antipsychotic.

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Addictology Paediatric psychiatry Psychiatry
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account